Background
In heavy chain amyloidosis (AH), fibrils derived from a truncated immunoglobulin heavy chain deposit in the kidney resulting in proteinuria, and the diagnosis usually requires a renal biopsy [1] . T-cell large granular lymphocytic leukemia (T-LGL) is a rare hematological malignancy that currently has no standard therapy. This report is of a rare case of T-LGL associated with renal AH and discusses the approach to management.
Case Report
In February 2017, a 57-year-old woman presented with symptoms of fatigue, nausea, weight gain, and dyspnea on exertion, and progressive proteinuria. She denied frequent infections, bleeding or bruising. A cardiac workup, including a recent cardiac stress test, was negative. She denied any symptoms of carpal tunnel syndrome but reported vague arthritis pain, both constipation and diarrhea in keeping with irritable bowel syndrome, and occasional episodes of choking. Her family history included a father with a diagnosis of Hodgkin's lymphoma and melanoma and a sister with a history of chronic multiple myeloma. Table 1 is a summary of the patient's laboratory findings at her initial presentation to our clinic in February 2017.
In her past medical history, she had been diagnosed with hypertension for several years. In 2002, she presented with lymphocytosis of 40-50%, which gradually increased to 70%, with mild neutropenia (between 900-1,200/μL), but with normal platelet and hemoglobin levels. A diagnosis of T-cell large granular lymphocytic leukemia (T-LGL) was made, which was never treated. In 2004, she was diagnosed with chronic kidney disease (CKD), which was attributed to chronic hypertension. Between May 2015 and October 2016, her proteinuria increased from 0.5 g/day to 1.5 g/day. A renal biopsy was performed at an external institution in November 2016 that showed glomerulosclerosis and extensive glomerular deposits of eosinophilic material that stained positively with the histochemical stain, Congo red, consistent with a diagnosis of renal amyloid. The renal histology also showed interstitial fibrosis, and moderate arterial and arteriolar sclerosis, consistent with hypertensive nephropathy. A diagnosis of renal amyloidosis was made. Table 2 shows the 24-hour urine protein measurements between 2015 and 2018.
At her initial presentation, a bone marrow aspirate and bone marrow biopsy were both negative for the presence of amyloid. Kappa and lambda free light chains (FLC) were 15.7 mg/L and 27.3mg/L, respectively. Serum immunofixation (SIFE) demonstrated an IgM kappa and free lambda light chains (LCs), and urine immunofixation (UIFE) showed free lambda LCs. The bone marrow biopsy contained two populations of plasma cells, 10-15% IgG lambda, and 5% IgG kappa. Flow cytometry of the bone marrow cells, using immunofluorescence, showed <1% of CD38-positive cells. Approximately 58% of the cell population consisted of neoplastic lymphocytes, which were positive for CD45, CD3, CD8, CD16, and CD57 and expressed alpha-beta T-cell receptor antigens with loss of CD7, CD5, consistent with a diagnosis of bone marrow involvement by T-LGL.
The patient's echocardiogram, electrocardiogram (ECG), endoscopy and barium swallow were normal. Pulmonary function testing to evaluate her dyspnea was normal. In March of 2017, mass spectrometry on renal tissue samples was performed at the Mayo Clinic and confirmed a diagnosis of immunoglobulin heavy chain amyloidosis (AH). The amyloid deposits were mostly restricted to the glomeruli and displayed gamma 1 heavy chain restriction with no other findings of paraprotein disease. Moderate chronic changes of the parenchyma were seen, including glomerulosclerosis.
At her initial evaluation at our clinic, the patient had symptoms of depression, and she commenced treatment with bupropion, which initially improved her symptoms and function. She returned to work, and given that there are no standard treatment guidelines we recommended initial observation. Following initial treatment by observation alone, over a year, her symptoms of fatigue returned with associated proteinuria (Table 2) , and treatment was initiated with the triple drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD) with ongoing consideration of future hematopoietic stem cell transplantation (HSCT).
Discussion
Amyloid fibrils consist of monoclonal light chains in AL amyloidosis, and the amyloid fibrils in heavy chain amyloidosis, or AH amyloidosis, are from fragments of immunoglobulin heavy chains. Renal involvement is common in both AL and AH amyloidosis. However, there are no standard treatment options for renal AH amyloidosis. In the literature, there have been two previously published reports of patients with renal AH who had a hematologic response following chemotherapy with combined oral melphalan, bortezomib, and steroids and autologous hematopoietic stem cell transplantation (HSCT), but only one had a renal response [2] . In a series of 16 patients with renal AH and AL amyloidosis [3] , the majority of patients received chemotherapy with or without HSCT, while clinical observation alone was also an option. In this cohort, cardiac involvement was less common and bone marrow biopsy was less likely to be positive for AH amyloid than in AL amyloid [3] . The median 24-hour urine protein was 5 gm and patients with renal AH amyloid tended to have a better renal response and better overall survival when compared with patients with renal AL amyloid (p=0.03) [3] .
Currently, treatment for T-cell large granular lymphocytic leukemia (T-LGL) is reserved for patients with symptomatic disease, neutropenia with recurrent infections, symptomatic anemia, thrombocytopenia, or autoimmune conditions. Monoclonal gammopathies can occur in association with T-LGL [4, 5] , which supports underlying immune dysregulation, which may lead to amyloid deposits in the kidney. There is no BNP -B natriuretic peptide; UPEP -urine protein electrophoresis; UIFE -urine immunofixation; SPEP -serum protein electrophoresis; SIFE -serum immunofixation; INR -international normalized ratio; PTT -partial thromboplastin time; BUN -blood urea nitrogen; AST -aspartate aminotransferase; ALT -alanine aminotransferase.
standard treatment for symptomatic T-LGL, although immunosuppressive therapy, including methotrexate, cyclophosphamide, and cyclosporine, in combination with prednisone or as single agents, are part of the initial first-line treatment [6, 7] . Cyclophosphamide is included in cyclophosphamide, bortezomib, dexamethasone (CyBorD) regimen, which was used in this case to treat both her amyloidosis and T-LGL. Expansion of T-LGL with progressive pancytopenia and repopulation of CD8+, CD57+ T-cells has been described following allogeneic HSCT [8, 9] , but the current consensus is that HSCT does not have a role in the treatment of T-LGL [6] . There have been several previously published cases of patients with AH with an underlying lymphoplasmacytic lymphoma [3, 10, 11] . In 2007 Picken et al. [1] commented that AH amyloidosis is almost always associated with some form of plasma cell or B-cell lymphoproliferative process.
In October 2017, the patient's proteinuria increased to >2.5 g/day and she reported symptoms of increased fatigue, dyspnea on exertion, and lower extremity edema. Given her symptoms of irritable bowel syndrome and neuropathic symptoms, she was not an ideal candidate for bortezomib, lenalidomide, or cyclophosphamide due to the side effect profile associated with these agents. Aggressive therapy with HSCT with a CD34-selected autograft focusing on the most primitive progenitor cells might reduce the risk of T-LGL progression. Daratumumab is a human monoclonal antibody that binds to CD38 and has been reported to result in rapid responses in patients with multiple myeloma and has been reported safe and effective in patients with AL amyloidosis [12] [13] [14] . Daratumumab has been shown to be effective in a case of refractory T-cell lymphoma [15] , but there is no data on its activity in T-LGL. Although treatment with daratumumab would have been well tolerated and had the potential to treat her T-LGL and heavy chain amyloid, daratumumab therapy was declined by the patient's medical insurer and so she was treated with CyBorD. Currently, the patient is undergoing symptomatic treatment and has improved hematologically with a reduction in 24-hour proteinuria to 1.7 g/day ( Table 2) .
Conclusions
This report has described a rare case of T-cell large granular lymphocytic leukemia (T-LGL) and immunoglobulin heavy chain amyloidosis (AH) involving the kidney. Currently, there is no standard therapy for T-LGL, and treatment, in this case, was with the triple drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD), with ongoing consideration of future hematopoietic stem cell transplantation (HSCT). Renal AH is an uncommon form of amyloidosis, and as this case demonstrated, mass spectrometry is a helpful proteomic diagnostic method for confirming the diagnosis of renal immunoglobulin heavy chain amyloidosis and in differentiating between AH and AL. This case report has supported previous findings that patients with renal heavy chain amyloidosis typically have no cardiac involvement, less Congo red positivity of the bone marrow, and have improved survival. As novel therapeutic agents become available, it is anticipated that improved treatments for amyloidosis and for T-LGL will improve patient prognosis.
